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Fibroblast growth factor homologous factors (FHFs) are intracellular proteins which regulate 
voltage-gated sodium (Nav) channels in the brain and other tissues. FHF dysfunction has been 
linked to neurological disorders including epilepsy. Here, we describe two sibling pairs and three 
unrelated males who presented in infancy with intractable focal seizures and severe 
developmental delay. Whole-exome sequencing identified hemi- and heterozygous variants in 
the N-terminal domain of the A isoform of FHF2 (FHF2A). The X-linked FHF2 gene (also 
known as FGF13) has alternative first exons which produce multiple protein isoforms which 
differ in their N-terminal sequence. The variants were located at highly conserved residues in the 
FHF2A inactivation particle that competes with the intrinsic fast inactivation mechanism of Nav 
channels. Functional characterization of mutant FHF2A co-expressed with wild-type Nav1.6 
(SCN8A) revealed mutant FHF2A proteins lost the ability to induce rapid-onset, long-term 
blockade of the channel while retaining pro-excitatory properties. These gain-of-function effects 
are likely to increase neuronal excitability consistent with the epileptic potential of FHF2 
variants. Our findings demonstrate that FHF2 variants are a cause of infantile onset 
developmental and epileptic encephalopathy, and underline the critical role of the FHF2A 
isoform in regulating Nav channel function. 
 





Voltage-activated sodium channels (Nav) play an essential role in the generation and spread of 
action potentials in excitable tissues.1,2 Variants in Nav channels and their regulatory partners are 
a major cause of infantile onset developmental and epileptic encephalopathies (DEEs).3,4 DEEs 
are typically associated with developmental delay or regression, treatment-resistant seizures and 
electroencephalographic abnormalities.5,6 The developmental consequences of DEEs are due to 
frequent epileptiform activity in combination with the direct effects of the genetic variant.7,8  
 
Fibroblast growth factor homologous factors (FHFs) are intracellular proteins that bind to the C-
terminal domain of Nav channels to modulate their function and location.9–12 FHFs were initially 
identified due to their homology with fibroblast growth factors (FGFs).13 However, FHFs are not 
secreted by cells and have only limited ability to activate FGF receptors.9,14,15 There are four 
FHF genes in mammals (often referred to by their FGF names): FHF1 (FGF12 [MIM: 601513]), 
FHF2 (FGF13 [MIM: 300070], FHF3 (FGF11 [MIM: 601514]) and FHF4 (FGF14 [MIM: 
601515]).9 The FHF genes have multiple transcription initiation sites. The alternative first exons 
produces multiple isoforms with variable N-terminal domains.16 The isoforms differ in their 
localization and ability to regulate Nav channels.9 The FHF2 gene, located at Xq26.3-q27.1, is 
highly expressed in the developing and adult brain.9,13 FHF2 is also expressed in endocrine 
tissues, ovaries, skeletal muscle and the myocardium of the developing heart,17–19 FHF2 has been 
implicated in a variety of functions including microtubule stability, axonogenesis, neuronal 
migration,20 interneuron development,21 cardiac conduction 22 and thermogenesis.23 Here, we 




We identified seven individuals from five unrelated families who presented with severe infantile-
onset seizures. Individuals 1 and 2 were a brother and sister from family A (Figure 1A) who had 
whole-exome sequencing (WES) as part of the Wales Epilepsy Research Network (WERN) 
family study. Individuals 3 and 4 were brothers from family B who had WES as part of the 
Deciphering Developmental Disorders (DDD) study.24 Individuals 5 from family C had WES 
performed by GeneDx. Individuals 1 to 5 shared the same seemingly de novo missense variant in 
FHF2, chrX (GRCh38/hg38):g.138710973G>A, NM_004114.5: c.31C>T, p.(Arg11Cys). 
Individual 6 from family D also had WES as part of the DDD study. Individual 6 had a different 
nearby variant in FHF2, chrX (GRCh38/hg38): g.138710963C>G, NM_004114.5: c.41G>C, 
p.(Arg14Thr). Parental testing for this individual was not possible. Individual 7 from family E 
had trio whole-genome sequencing (WGS) performed by Cipher Gene. Individual 7 was mosaic 
(7 variant reads out of 17 total) for a different missense change at the Arg11 residue, chrX 
(GRCh38/hg38):g.138710972C>G, NM_004114.5: c.32G>C, p.(Arg11Pro). The mosaicism was 
confirmed by WES (14 variant reads out of 26 total) and Sanger sequencing. Identification of 
individuals 5 and 7 was achieved via GeneMatcher.25 Maternal mosaicism is likely to explain the 
sibling recurrence in families A and B. This was not detected by WES or Sanger sequencing. 
Families A and B, and individual 6 also had WGS as part of the 100,000 Genomes Project.26 
WGS confirmed the variants in the affected individuals. The p.(Arg11Cys) variant was not 
detected in the mother of family A but the mother of family B had 2 variant reads out of 40 total, 
consistent with low-level mosaicism. Individuals who had evaluation or analysis beyond routine 
clinical care were part of research studies approved by either the Research Ethics Committee for 
Wales (09/MRE09/51) or the Cambridge South Research Ethics Committee (10/H0305/83 and 
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14/EE/1112). The parents and carers of the individuals gave consent for their publication in this 
report. 
 
The clinical features of the seven individuals are summarized in Table 1. Detailed case reports 
for the individuals are provided in the Supplemental Note. Shared features included global 
developmental delay and severe or profound intellectual disability. Individuals 2-4 and 6 were 
diagnosed with autism spectrum disorder. All seven individuals had treatment resistant epilepsy. 
Five presented in the neonatal period with episodes of apnoea and cyanosis. The predominant 
epilepsy phenotype was focal seizures often with secondary generalization. A range of other 
seizure types were reported including epileptic spasms, tonic seizures, gelastic seizures, absence 
seizures, drop attacks and generalized tonic-clonic seizures. The focal seizures were associated 
with motor features (eye twitching or head deviation), apnoeas, and oroalimentary automatisms 
(chewing or repeated swallowing). Autonomic features included drooling, ictal vomiting and 
skin flushing. EEGs found evidence of temporal lobe foci in some. Seizures were resistant to a 
wide range of anti-epileptic drugs (AED). Two individuals had vagus nerve stimulators 
implanted. Individual 2 underwent left anterior temporal lobectomy and partial amygdalo-
hippocampectomy at 7 years of age. She was seizure free for 2 years; however, the focal seizures 
resumed and at last review (13 years of age) she was having fortnightly clusters despite three 
AEDs. Constipation was common in the group and one person (individual 1) had subtotal 
colectomy and ileostomy due to chronic constipation and recurrent severe abdominal pain. 
Physical examination of the individuals revealed normal or reduced muscle tone. There was no 
spasticity or hyperreflexia. Subtle dysmorphic features were noted but these were variable and 
may reflect the effects of AEDs and facial hypotonia. Photographs of individuals 1-4 are shown 
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in Figure 1A. Brain MRI scans in infancy were normal. Brain MRI scans of individual 2 at 6 
years of age and individual 7 and 3 years of age found evidence of cerebral atrophy. Individual 4 
had a 3T MRI brain scan at 13 years of age which showed symmetrical T2 hyperintensity of the 
hippocampal body and head with loss of definition of the internal architecture.  
 
The three variants, p.(Arg11Cys), p.(Arg11Pro) and p.(Arg14Thr), identified in the affected 
individuals are not present in population databases such as gnomAD.27 The variants were 
predicted to be deleterious by a range of in silico prediction programs (Table S1).28 The variants 
are located in exon 1A of FHF2. This exon encodes the N-terminal domain specific to the A 
isoform of the FHF2 protein (FHF2A) (Figure 1B).  The 1A exon is highly conserved across 
species and across all four FHF genes (Figure 1C). The Arg11 and Arg14 residues are 
completely conserved in all sequences.  Overall, the FHF2 gene is moderately intolerant to 
variation (gnomAD missense z-scores range from 1.59 to 2.11 for the different isoforms). 
However, the N-terminal of the A isoform (ENST00000315930.6) is particularly constrained 
with no gnomAD missense variants in the first 21 residues.27 In contrast, there are 5 gnomAD 
synonymous variants in the same region and 7-10 missense variants in the first 21 residues of the 
other FHF2 isoforms. 
 
The FHF2 exon 1A missense variants are at residues known to contribute to long-term Nav 
channel block.29 Nav channels cycle between closed (or resting), open and inactivated states 
(Figure 2A).30 Membrane depolarization from resting potential to the voltage threshold for Nav 
channel activation triggers the shift from a closed to an open state. The channel is open for 
around a millisecond before inactivation occurs. The majority of channels are inactivated by a 
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mechanism intrinsic to the Nav channel but around one third are inactivated by an 'inactivation 
particle' contained by the N-terminal domain of A-type FHF proteins.31 Channels can recover (or 
reprime) to a closed state upon hyperpolarization of the membrane. Recovery from the intrinsic 
Nav inactivation mechanism is complete within 10 ms while recovery from FHF-mediated 
inactivation takes hundreds of milliseconds. Channels may also proceed directly from a closed to 
an inactivated state (‘steady-state’ inactivation). A-type FHF isoforms have a mixture of 
inhibitory and pro-excitatory effects on the inactivation mechanisms of Nav channels. Repeated 
cycles of channel opening promote accumulation of channels in FHF-mediated long-term block. 
This contributes to a run-down in Nav channel availability immediately following a cluster of 
action potentials.31,32 Through this inhibitory mechanism, A-type FHF isoforms can induce 
spike-frequency adaptation, also termed accommodation.29  One potential function of 
accommodation is to prevent persistent excitation of neural networks and seizures.33,34 In 
contrast, A-type FHF isoforms also induce a depolarizing shift in the voltage dependence of Nav 
channels for steady-state inactivation.31,32,35,36 This is pro-excitatory because it limits steady-state 
inactivation of channels at resting potential. Another pro-excitatory effect of A-type FHF 
isoforms is to slow the intrinsic fast inactivation of channels during membrane depolarization 
and action potential initiation.10,32 
 
To assess the functional effects of FHF2A p.Arg11Cys and p.Arg14Thr on neuronal sodium 
channel gating, we measured sodium currents during voltage clamp protocols in FHF-negative 
Neuro2A cells co-transfected with constructs expressing Nav1.6 (SCN8A) and either wild-type 
FHF2A (FHF2AWT) or a mutated version (FHF2AR11C or FHF2AR14T). Detailed descriptions of 
the plasmids, mutagenesis, transfection of Neuro2A cells and measurement of sodium currents 
10 
 
are provided in the Supplemental Material and Methods.  All procedures parallel those we have 
described previously.29,31 Patched cells were depolarized to 0 mV for four 16 ms intervals 
separated by 40 ms recovery periods at -90 mV to allow for sodium channel recovery from 
intrinsic fast inactivation (Figure 2B).  In cells expressing FHF2AWT, transient Nav1.6 sodium 
current amplitude diminishes with each depolarization cycle (Figure 2C,F), reflecting 
accumulating long-term inactivation of Nav1.6.  By contrast, the extent of long-term channel 
inactivation is greatly reduced in cells expressing FHF2AR11C (Figure 2D,F), while the sodium 
currents during four depolarization cycles in cells expressing FHF2AR14T are indistinguishable 
from those in cells without FHF2 (Figure 2E,F), demonstrating that FHF2AR14T is incapable of 
promoting Nav1.6 accumulating long-term inactivation. 
 
In a second experiment to assess the effects of the FHF2A variants on long-term channel 
inactivation, cells were subjected to multiple rapid depolarization cycles followed by a -90 mV 
recovery period of varying duration (20 ms to 1 s) before a subsequent test depolarization.  In 
cells expressing FHF2AWT, near-full recovery of Nav1.6 from long-term inactivation required 
one second, while in cells expressing FHF2AR11C channels fully recovered by 200 ms (Figure 
2G).  Cells expressing FHF2AR14T again show no evidence of Nav1.6 long-term inactivation, as 
channels fully recover as quickly as in cells lacking FHF (Figure 2G). 
 
Although impaired in their ability to promote Nav1.6 long-term inactivation, FHF2AR11C and 
FHF2AR14T are expressed at comparable levels to FHF2AWT in transfected cells and the mutant 
isoforms associate with Nav1.6 as effectively as does FHF2AWT, as demonstrated by co-
immunoprecipitation (Figure S1). This indicates the variants do not disrupt binding of FHF2 to 
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the C-terminal cytoplasmic tail of Nav channels. This binding is mediated by the conserved β-
trefoil core domain shared by all FHF isoforms.16,37 In contrast, residues 2-21 of A-type FHFs 
contain the inactivation particle that competes with the intrinsic fast inactivation mechanism of 
Nav channels following membrane depolarization.31 The reduced ability of mutant FHF2A to 
promote Nav1.6 long-term inactivation indicates the N-terminal variants impair function of this 
inactivation particle. Mutagenesis of FHF2A to replace Arg11 or Arg14 with glutamine 
prevented binding of an antibody specific to the N-terminal of A-type FHFs.29 This suggests that 
both residues are prominent surface features. Both FHF2AR11Q and FHF2AR14Q showed impaired 
accumulation of long-term inactivation and hastened recovery of Nav channels while having little 
effect on the ability of FHF2A to modulate steady-state inactivation. These findings are 
consistent with our results for the two DEE-associated variants which suggest the effects are due 
to loss of the cationic arginine side chains rather than specific effects of the substituted side 
chains. 
 
Consequently, we tested the ability of mutant FHF2A proteins to modulate the voltage 
dependence of Nav1.6 steady-state inactivation.  As shown in Figure 2H, FHF2AR11C and 
FHF2AR14T raised the V1/2 for channel steady-state inactivation by 17 mV and 19 mV, 
respectively, which was statistically indistinguishable from the 18 mV V1/2 elevation of Nav1.6 
inactivation mediated by FHF2AWT.  Therefore, the DEE-associated variants preserve this pro-
excitatory property of FHF2A while suppressing the sodium channel long-term inactivation 




The FHF2 exon 1A missense variants join a growing number of isoform-specific variants that 
have been reported in epileptic encephalopathies.38–40 Around 30% of neonatal epilepsy genes 
have brain-expressed alternative coding regions, suggesting that isoform-specific variants are 
relatively common.41 However, variants in alternative transcripts are prone to being missed or 
misinterpreted due to problems with panel designs and genome annotation.42 This may have 
contributed to FHF2-DEE not being recognized until now. 
 
Deleterious variation in FHF genes has previously been associated with neurological disorders. 
In 2015, a balanced reciprocal translocation, t(X; 14) (q27; q21), disrupting FHF2 was reported 
segregating in a family (two brothers and their mother) with Genetic Epilepsy and Febrile 
Seizures Plus (GEFS+ [MIM: 604233]).43 One of the brothers and other members of their 
extended family had cognitive impairment. The translocation breakpoint occurred after two of 
the alternative first coding exons of FHF2 (exons 1V and 1Y, using the notation from Munoz-
Sanjuan et al., 2000 44 but before the first coding exons of the two main isoforms, exon 1A (also 
known as 1S, employed by FHF2A) and exon 1B (also known as 1U, used by FHF2B). The 
predicted consequence was to disrupt the minor isoforms of FHF2 which use the more 5’ exons.  
There was a subsequent report of a de novo missense variant in FHF2 (NM_004114.5: 
c.638C>T, p.(Thr213Met)) in one individual with mild febrile seizures, normal development and 
facial edema.45 However, the significance of this variant was uncertain. 
 
Gain-of-function variants in FHF1 (FGF12) have recently been identified in individuals with 
DEE (MIM: 617166).4,46,47 There are strong similarities between FHF1- and FHF2-DEE. FHF1-
DEE (familial early-onset epileptic encephalopathy with progressive cerebral atrophy) presents 
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with seizures in early infancy and severe developmental delay. The epileptic phenotypes of 
FHF1 and FHF2 disease are similar. FHF1-DEE is typically associated with focal epilepsy or a 
combined generalized and focal epilepsy.48 Tonic seizures with autonomic signs are common in 
both FHF1- and FHF2-DEE. Other seizure types reported in both disorders include generalized 
tonic-clonic seizures, epileptic spasms, absence and myoclonic seizures. The epilepsy in FHF1-
DEE is often intractable but responsiveness to phenytoin (a sodium channel blocker) has been 
noted.47–49 Individuals 3 and 4 in our series gained at least transient benefit from phenytoin. The 
other subjects have either not been given phenytoin or their response is unknown.  
 
Individuals with FHF1-DEE have been noted to have progressive cerebellar atrophy, potentially 
as a result of excitotoxic damage.4 Loss-of-function variants in FHF4 (FGF14) have also been 
associated with cerebellar dysfunction (and occasionally cerebellar atrophy) as the cause of 
spinocerebellar ataxia type 27 (MIM: 609307).50,51 In contrast, structural and functional 
abnormalities of the cerebellum were not observed in FHF2-DEE. Different gene  expression 
patterns may explain this difference as FHF1 and FHF4 are both highly expressed in the 
cerebellum while FHF2 is not.9,18 An additional difference between FHF1- and FHF2-DEE is 
that the recurrent FHF1-DEE variant is present in both the A (NM_021032.4: c.341G>A, 
p.(Arg114His)) and B isoforms (NM_004113.6:c.155G>A, p.(Arg52His)). This residue is 
located in the B4-B5 loop of the core FHF domain that contributes to the highly conserved 
structural interface between FHF proteins and the cytoplasmic tails of Nav channels.4 
Substitution of FHF1A Arg114/FHF1B Arg52 to other amino acids increased the depolarizing 
shift in the voltage dependence of steady-state inactivation of Nav1.6 (Figure 2A). The shift of 
this voltage dependence (which increases the availability of resting channel) was greatest for the 
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mutant form of the A isoform. In contrast, FHF2-DEE variants do not alter steady-state 
inactivation, instead they disrupt the ability of N-terminal inactivation particle to cause long-term 
inhibition of Nav channels. 
 
We recognize the need for caution in interpreting the significance of the variant in female 
individual 2 when FHF2 is X linked and the other individuals are male. However, individual 2’s 
epilepsy phenotype was strikingly similar to her brother’s and no other cause for her DEE was 
identified. X-chromosome inactivation assays found no significant skewing in her blood (65:35 
at the AR gene [MIM: 313700] and 55:45 at the ZNF261 gene [MIM: 300061]) suggesting the 
variant allele is active in a moderate proportion of her somatic tissues (although this may not 
reflect the inactivation pattern in her brain). Consistent with being heterozygous, individual 2 
had a milder phenotype than her hemizygous brother and the other males. A difference in 
severity was also present in the GEFS+ family with the balanced translocation described by 
Puranam et al.43 The mother with the translocation had febrile seizures in infancy but was 
neurologically normal and seizure free in adulthood. In contrast, her sons had febrile seizures, 
temporal lobe epilepsy and one had cognitive impairment. A sex difference is recapitulated by 
the Fhf2 knockout animal model. Female heterozygous knockout mice are viable but have 
increased susceptibility to hyperthermia-induced seizures.43 The brains of female heterozygous 
knockout mice demonstrate mosaic expression of wild-type and null Fhf2 alleles (C. Marra and 
M. Goldfarb, unpublished data).  There is evidence for reduced embryonic survival of male mice, 
although this may be dependent on strain background.20,22,43 Surviving male knockout mice 
experience progressive conduction failure in response to higher body temperatures. No cardiac 
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conduction abnormalities were observed in our series. However, loss-of-function partial or whole 
gene deletions are likely to have different effects from gain-of-function missense variants. 
 
FHF2 was historically considered a candidate gene for Börjeson-Forssman-Lehmann syndrome 
(BFLS [MIM: 301900]) an X-linked intellectual disability syndrome associated with 
dysmorphism, epilepsy, obesity and hypogonadism.20,52 An individual with BFLS-like features 
(including neonatal-onset seizures) had a maternally-inherited Xq26q28 duplication.52 The 
breakpoint was mapped to a ~400kb interval in Xq26.3, a region which contains FHF2. BFLS 
was subsequently mapped to variants in PHF6 (MIM: 300414) a gene nearby in Xq26.2. The 
clinical significance of copy-number variation involving FHF2 remains uncertain. However, 
metrics of dosage sensitivity (haploinsufficiency score 3.17, top 5th percentile) 53 and mutational 
constraint (probability of being loss-of-function intolerant 0.97),27 and evidence from human and 
animal studies 20,22,43 suggests they are likely to have clinically significant effects. Notably, 
duplications of FHF1 have been reported in individuals with DEE.49,54 
 
A-type FHFs, including FHF2A, and slow-activating/deactivating voltage-gated potassium 
channels (Kv7.2 and Kv7.3) both contribute to attenuation of excitatory drive by either run-down 
of the sodium conductance or build-up of the potassium conductance, respectively.55,56 
Consequently, both of these processes contribute to spike frequency adaptation 
(accommodation), as documented in CA1 hippocampal pyramidal neurons.29,57,58  Variants in the 
genes encoding Kv7.2 or Kv7.3 (KCNQ2 [MIM: 602235] and KCNQ3 [MIM: 602232]) cause 
early-onset epilepsy phenotypes including DEEs.55,56  Our new findings regarding FHF2A 
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thereby suggest that disturbed spike frequency adaptation is an important mechanism in 
epileptogenesis. 
 
In conclusion, we have identified hemi- and heterozygous missense variants in the N-terminal of 
the A isoform of FHF2 as a cause of infantile onset DEE. Our functional results demonstrate that 
the variants lead to gain of function because they disrupt the ability of FHF2A to cause long-term 
inactivation of Nav channels while preserving pro-excitatory properties of FHF2A. Our study 
provides evidence for the critical role of the FHF2A isoform in regulating Nav channel function 
and neuronal excitability. 
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Table 1. Clinical and molecular findings in the individuals with N-terminal FHF2A variants 
Individual 1 (Family A) 2 (Family A) 3 (Family B) 4 (Family B) 5 (Family C) 6 (Family D) 7 (Family E) 
Age 15 y 13 y 19 y 12 y 2 y 3 m 5 y 5y 8m 























De novo Unknown Mosaic 
OFC -1.4 SD at 13y10m +0.8 SD at 6y9m -0.2 SD at 19y -1.4 SD at 12y5m -1.1 SD at 22m -2.5 SD at 5y -2.6 SD at 3y2m 
















6m, head and eye 
deviation, twitching 






6m, focal sz 
Epilepsy Focal sz at 2m. 
Generalised sz 
from 7 m 
Focal sz from 11 m. 
Never generalised. 
Focal sz at 2m. 
Flexor spasms from 
6m. 
Focal sz at 6m. 
Generalised sz 
from 2.5y. Now - 
episodes of NCSE, 
















6m. Later EEG 
suggestive of LGS 
Hypsarrhythmia at 
2.5y. EEG at 11y 








suppression at 23m 
Neurology Hypotonia, no 
hyperreflexia 
Normal tone and 
reflexes 












n/k Limb hypertonia. 
Positive Babinski 

















Hypothyroidism Atrial septal defect Regression at 14m 
 
Key: Variants based on transcript NM_004114.5; Age in y(ears), m(onths), w(eeks) or d(ays); AED, antiepileptic drugs; ASD, autism 
spectrum disorder;  EEG, electroencephalogram; EIMFS, epilepsy of infancy with migrating focal seizures; GTCS, generalized tonic-
clonic seizures; ID/DD, intellectual disability or developmental delay; LGS, Lennox-Gastaut syndrome; NCSE, nonconvulsive status 






Figure 1. Family pedigrees and locations of the FHF2A variants. (A) Pedigrees of families A-E 
with photographs of the affected individuals from families A and B. Genotypes are heterozygous 
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mutant (+/-), homozygous wild type (-/-), hemizygous mutant (+/0) and hemizygous wild type (-
/0). (B) Exonic models of the FHF2 transcripts showing the alternative 5’ coding exons. The 
FHF2A protein isoform is derived from the NM_004114.5 transcript which is initiated from an 
ATG start site in exon 1A (also known as exon 1S). The V, Y, U and S nomenclature originates 
from Munoz-Sanjuan et al., 2000.44 The 1A/1S exon encodes the N-terminal domain (NTD) of 
FHF2A (amino acid residues 1 to 62). The shared C-terminal exons encode the core fibroblast 
growth factor (FGF) domain (amino acid residues 67 to 198). The blue asterisk indicates the 
location of the breakpoint of the translocation described by Puranam et al.43 The red asterisks 
indicate the location of the DEE-associated missense variants. (C) The FHF2 (FGF13) 
substitutions are located at highly conserved residues in the N terminal domain of the A isoform. 
Homology alignments for human FHF2 (NP_004105.1, amino acid residues 1-28) and a range of 
orthologues and paralogues. Orthologues include chimpanzee (XP_001138460.1), rhesus 
macaque (NP_001252772.1), dog (XP_549294.2), cow (NP_001092362.1), mouse 
(NP_034330.2), rat (XP_006257654.1), chicken (XP_015133693.1), western clawed frog 
(XP_012824080.1) and zebrafish (XP_005173268.1). Paralogues include FHF1/FGF12 
(NP_066360.1), FHF3/FGF11 (NP_004103.1) and FHF4/FGF14 (NP_004106.1). The positions 





Figure 2. Functional characterization of the variants in the FHF2A N-terminal domain. (A) 
Scheme of voltage-dependent sodium (Nav) channel state transitions as modulated by A-type 
fibroblast growth factor homologous factors (FHFs), as described previously.29,31  Strong rapid 
depolarization results in transient opening of channels and sodium influx (vertical red arrow).  
Within milliseconds, channels intrinsically inactivate (leftward descending arrow).  When 
channels are physically associated with A-type FHF, the N-terminus (red triangle) competes with 
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the intrinsic Nav mechanism (blue circle) to rapidly induce long-term inactivation (rightward 
descending arrow).  Recovery to the closed state upon repolarization requires hundreds of 
milliseconds.  Long-term inactivation of channels is impaired in presence of the FHF2AR11C or 
FHF2AR14T (white asterisk).  A-type FHFs raise the voltage dependence of steady-state 
inactivation, preserving more channels in the closed (resting) state.  The pro-excitatory DEE-
associated FHF1R114H mutant protein further raises the voltage dependent of steady-state 
inactivation.4 (B) Voltage-clamp protocol for accumulating long-term inactivation used in C-E. 
The 40 ms intervals at −90 mV allow for full recovery from intrinsic fast inactivation, but only 
partial recovery from long-term inactivation, which has a far slower recovery rate. (C-E) 
Representative sodium current traces in Neuro2A cells expressing Nav1.6 together with either 
(C) FHF2AWT, (D) FHF2AR11C, or (E) FHF2AR14T. The variants impair channel long-term 
inactivation. (F) Analysis of long-term inactivation induced by wild-type and mutant FHF2A 
proteins. ‘n’ represents the number of transfected cells recorded for a given experimental 
protocol. The impaired long-term inactivation of FHF2AR11C and FHF2AR14T in comparison to 
FHF2AWT upon depolarizations 2,3,4 is highly significant (p < 10-7). (G) Analysis of Nav1.6 
recovery from long-term inactivation at -90 mV. Nav1.6 recovers faster in cells expressing 
FHF2AR11C or FHF2AR14T compared to cells expressing FHF2AWT.  (H) FHF2AR11C and 
FHF2AR14T retain the ability to induce depolarizing shift in voltage dependence of Nav1.6 fast 
inactivation. Both mutant FHF2A proteins retain ability to induce 17-19 mV depolarizing shifts 








This male individual is the second child of unrelated White British parents. He has an older sister 
who is healthy and a younger sister (individual 2) who also has infantile-onset epilepsy and 
developmental delay. He was delivered by ventouse at full term following an uncomplicated 
pregnancy.  His birth weight was 2.83 kg (-1.5 SD). In the first 24 hours of life he was noted to 
be restless and had four episodes of apnoea, cyanosis and lip smacking following feeds. His 
stomach and oesophagus were washed out to remove excess mucus. At 11 days of age he had 
another episode of apnoea and cyanosis. He was resuscitated and taken to hospital. 
Gastroesophageal reflux was suspected based on the results of a barium swallow.  
 
At 4 months of age individual 1 had further events associated with staring, twitching of the right 
eye and posturing of his right arm. An MRI brain scan was normal, and an ictal 
electroencephalogram (EEG) showed sharp waves over his left temporal region. He had his first 
episode of convulsive status epilepticus at 7 months of age. He went on to develop slowly with 
no period of regression. At 8 months of age he could roll over with prompting but could not sit 
without support. He could reach out for objects directly in front of him. His seizures were 
characterised by staring, vomiting and lip twitching.  Events lasted 10-20 seconds but 
occasionally up to 1 minute. His sleep was sometimes fragmented, with frequent episodes of 
inappropriate laughing or giggling. These were thought to be ictal. 
 
By 9 months of age the seizures had evolved to start with a gag or vomit, and excess salivation. 
He would then swallow, his eyes would deviate to the right, and his right eye would twitch; they 
would end with a ‘nervous’ laugh. In some cases, he would hold his breath, become cyanosed 
and have a generalised seizure. On examination, his occipitofrontal circumference (OFC) was 
44.5 cm (-1.5 SD). There was no overt laterality. His tone was slightly low. He was relatively 
inactive in terms of gross motor movements when placed prone or supine.  He could, however, 




A further EEG at 9 months of age showed an asymmetric record with almost continuous 
discharge from the right temporal leads.  The background amplitude was slightly higher than 
expected for his age.  A diagnosis of epilepsy of infancy with migrating focal seizures was 
considered. However, the EEG findings were not felt to be consistent with this classification as 
there was no shifting of foci of ictal onset between hemispheres during the same EEG recording. 
 
Individual 1 had a seizure-free period around 10-12 months of age (on lamotrigine, topiramate, 
vigabatrin and sodium valproate). Towards the end of this period the vigabatrin was stopped. 
This coincided with him becoming more alert and responsive. At 12 months of age he was more 
visually attentive and became more interested in toys but was not reaching out for them.  He 
could stand with support. OFC at 12 months was 45.5 cm (-1.8 SD). His muscle tone continued 
to be slightly low. Eye examination at 13 months revealed symmetrical corneal reflexes with no 
nystagmus.  His fundi were normal. He had slight astigmatism but it did not require correction. 
At 15 months of age he had 2 prolonged seizures, the first was predominantly left sided and 
lasted 45 minutes, and the second was predominantly right sided and lasted 30 minutes.  This 
was in the context of him having an unspecified (possibly viral) illness. 
 
On review at 20 months of age individual 1 was having around 3 seizures per week (this was 
after stopping lamotrigine).  These typically occurred early in the morning and lasted for about a 
minute. He would initially vomit or gag, following which his head and eyes would deviate to the 
right.  His right eye would twitch followed by twitching of his right arm. On examination, his 
tone was normal although his feet were still quite mobile and his back was quite rounded. OFC at 
22 months was 46 cm (-3 SD). 
 
A ketogenic diet was employed between 20-23 months of age however individual 1’s seizure 
frequency increased. This coincided with a change of seizure morphology to include truncal 
flexion at the start of seizures. He would then start with focal involvement on the right which 





At 24 months of age individual 1 was having about 25 seizures per month. The seizures were 
generally short and stereotyped. He would initially flex his trunk, followed by trembling and 
clawing at his face. He would then relax slightly, followed by a gustatory component 
(swallowing, chewing, jaw movement and vocalisation). Examination showed profuse drooling, 
low axial muscle tone and occasional athetoid and dystonic movements. A 24-hour EEG at 2 
years of age captured a seizure during sleep. At onset there was diffuse alpha activity followed 
by rhythmical sharpened slow wave activity in the right posterior hemisphere leads, thereafter 
with diffuse slowing over both hemispheres. Interictal epileptiform activity was seen over the 
right posterior hemisphere. Clinically, the event lasted 4 minutes and manifested as deep 
breathing, with oromotor automatisms. There was an ictal tachycardia. 
 
At 29 months of age individual 1 was commando crawling and was aware of bottles put into his 
hands. His sleep pattern was still poor and he was treated with melatonin. The frequency of his 
focal seizures ranged from daily clusters to single isolated seizures once a week. The typical 
duration was 1-2 minutes but sometimes up to 3 minutes. Seizures involved head deviation to the 
left, eye twitching and repetitive swallowing. Both arms would flex but towards the left side of 
his body. He would then have a clonic phase and becoming dusky around the mouth. Events 
were usually nocturnal and he would go back to sleep afterwards. At 2½ years of age a vagus 
nerve stimulator (VNS) was fitted. This improved recovery from seizures but not the frequency. 
Individual 1 sat unaided at 4 years of age. 
  
At 5 years of age individual 1 was not playing with toys but liked lights and to tap objects. He 
had a good appetite and fed orally. He could chew well but continued drooling. On examination, 
he had deep-set eyes but was not dysmorphic. He was well grown and had normal hand creases. 
His neurology was normal. OFC was 50 cm (-1.9 SD). Constipation was a persistent problem for 
individual 1 from infancy onwards. He had increasing problems with abdominal discomfort 
around the age of 7 years. Blood tests for celiac disease and thyroid function were normal. An 
EEG at age 8 years (on vigabatrin, sodium valproate, topiramate and oxcarbazepine) showed 





At 8 years of age a barium meal and follow through concluded that he was grossly constipated, 
with poor colonic motility despite large doses of bulk-forming agents and bowel stimulants.  At 9 
years 10 months of age he underwent elective sub-total colectomy and ileostomy. However, the 
abdominal pain continued and at 11.5 years of age he had a laparotomy to divide adhesions and 
to release a stoma constriction. Post-operatively his weight was 36.4 kg (+0.0 SD) and he was 
feeding well orally. The revised stoma functioned well without difficulties. Despite the 
operations individual 1’s abdominal pain continued in paroxysms every 7-9 days. Visceral 
hyperalgesia was raised as a possible explanation although the discomfort seemed to respond to 
an anti-spasmodic agent. His focal seizures continued during this period. Other seizure types 
included drop attacks and gelastic seizures in the early hours of the morning. 
 
When reviewed at 13 years of age individual 1 could take his own weight when standing but was 
not walking independently. His parents felt his concentration had improved over the previous 
two years. Daily routines were important for him. He was not talking or pointing but had 
responsive eye gaze and vocalised when he wanted something. He would occasionally comfort 
rock, hand flap or hyperventilate. Examination at this stage showed that his weight was 55kg 
(+0.7 SD) and OFC 53.4 cm (-1.4 SD). He had mild scoliosis and gum hypertrophy. 
Neurological examination found low truncal tone, with tight hamstrings but no lateralising signs. 
 
Individual 1 continued to have a range of seizure types. He had daily focal seizures and weekly 
generalised tonic-clonic seizures (GTCS). The focal seizures were short, typically 1-2 minutes. 
They were often associated with repeated swallowing or gagging, breath holding, and increased 
salivation. His arms would tighten and then start jerking. His head would turn to the right (or 
sometimes the left). He would go pale and his lips might go blue. Some events would begin with 
his throwing back his head, splaying out his arms, and shouting as if frightened. He would be 
happy with intermittent giggling afterwards, with mouth and eye twitching for a few minutes. 
With generalization the focal component would be followed by him going blank and extensor 
posturing. An asymmetric clonic phase would then follow, with his arms and legs jerking, 
particularly on the right. His face would become red and blotchy. These seizures were 
occasionally prolonged (10-90 minutes long). These were characterised by jaw, eye and limb 
twitching, and being very unresponsive. Sometimes he would vomit. His anticonvulsant therapy 
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included sodium valproate, phenobarbitone, gabapentin, zonisamide and buccal midazolam (as 
required). 
 
Individual 1’s genetic testing has included routine karyotype, array comparative genomic 
hybridization (aCGH), single gene testing for Fragile X syndrome, CDKL5, SCN1A (including 
dosage analysis) and a 134-gene infantile epilepsy panel. The results were all normal. 
 
Summary of antiepileptic medications (Figure S2, current anticonvulsant drugs underlined):  
 
Vigabatrin  4m(onths) – 11m (“alert and more responsive after coming off”), 26m – 113m 
Sodium valproate  4m – 18m, 33m – 36m, 106m +  
Lamotrigine  4m – 18m, 108m +  
Topiramate  9m – 110m 
Levetiracetam  18m – 24m 
Oxcarbazepine36m – 107m 
Pregabalin  48m – 49m 
Rufinamide  56m (“many jerks”), 105m (“made seizures worse”, “drugged up”), 108m – 149m 
Sulthiame  63m – 72m (“less seizures after coming off”) 
Clobazam  100m – 106m 
Phenobarbital 107m, 113m – 173m 
Gabapentin  154m +  
Zonisamide  157m +  




This female individual is the third child of White British parents. She is the younger sister of 
individual 1. She was born by elective caesarean section at 39 weeks gestation following a 
uneventful pregnancy and required no special care. Cord pH was normal. Apgar scores were 9 at 
1 minute and 10 at 5 minutes. Her biometry at birth was OFC 33 cm (-0.8 SD) and weight 3.13 
kg (-0.2 SD). At 11 days of age she presented with several episodes of becoming dusky around 
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feeds and shallow breathing. She had a respiratory arrest. She was resuscitated, admitted to the 
Paediatric Intensive Care Unit and given a loading dose of phenobarbital. The apnoeic events 
stopped and she was discharged from hospital after 9 days. Gastroesophageal reflux was 
suspected and she was not given further anticonvulsant drugs at this stage. An interictal EEG at 
age 1 month was normal with no photosensitivity. 
 
When reviewed at 7 weeks of age she was feeding and growing well. Her OFC was 37.5 cm 
(+0.5 SD) and weight 4.65 kg (+0.8 SD). She was smiling responsively and had good head 
control. Limb tone and movement were normal. Her parents thought she was able to do more 
than her brother at the same age. She sat unsupported at 7 months of age. An interictal EEG at 10 
months of age was normal apart from a reduction of sleep spindle and beta activity over the left 
hemisphere. There was no photosensitivity. At 11 months of age individual 2 had an upper 
respiratory tract infection and started to have focal seizures. The seizures were similar to but less 
severe than her brother's. The seizures involved lip smacking, going dusky around the mouth, 
repeated swallowing movements, eye deviation to left, and facial twitching on the left side. 
There was no generalisation. Her development and neurological examination was normal. 
 
Individual 2 walked unsupported at 15 months of age. An interictal EEG at 14 months found 
excess background slowing. Ophthalmology examination at 19 months of age was normal. A 
cranial MRI at 20 months of age was normal. By 21 months of age she was having clusters of 
seizures which lasted for about 2 days every 6 weeks.  Her parents began to notice some slowing 
of her development compared to her peers. An EEG at 23 months (on sodium valproate and 
vigabatrin) showed diffuse fast activity in the majority of leads with some non-specific mixed 
slow waves over the central and posterior regions. No epileptiform activity was noted and there 
was no photosensitivity. At 24 months of age individual 2 was walking and running, but her gait 
was still immature. She had difficulty standing from sitting and had to pull herself up on 
furniture. She could finger feed and use a spoon. She was noted to have speech and language 
delay and drooled profusely. She said ‘dada’ and ‘mama’ but not consistently. She had recurrent 
episodes of otitis media and at 28 months she was diagnosed with bilateral middle ear effusions. 




Reviewed at 31 months she had mild developmental delay, no speech and drooled profusely. Her 
growth was normal and she had good eye contact. Her seizures were well controlled on 
vigabatrin and topiramate but her parents reported general cognitive decline. Her development 
was better than her brother and she had less seizure activity. At 3 years of age her motor skills 
were better than her language abilities. She could use a pincer grip and was precise with buttons. 
She could climb stairs while holding hands, drink from a feeder cup, smile and vocalise. On 
examination her OFC was 48 cm (-2.1 SD). She was not dysmorphic but had a high palate and 
was slightly prognathic. 
 
At 3½ years of age her seizures increased in frequency. The seizures were focal and typically 
involve her gulping, gagging or vomiting. Her lips would go blue. She would then have eyes 
deviation to the left with mouth twitching. The seizures were short and she would recover 
quickly from them. A short interictal EEG at 3 years 6 months of age (on lamotrigine, 
levetiracetam and vigabatrin) found diffuse fast activity overlying slower rhythms but no focal 
events. At 3 years 8 months of age she had a generalised seizure at home which was similar in 
morphology to her brother’s.  
 
At 4 years of age she was having frequent short focal seizures sometimes as clusters and 
sometimes as single isolated events. Her seizures were associated with eye deviation to the left 
(or sometimes right), lips going blue, and often ictal vomiting. They did not generalise. Her 
weight was 18.41 kg (+1.0 SD) and height 105.4 cm (+1.0 SD). EEG at 4 years of age showed 
diffuse fast activity mixed with non-specific slow wave activity but no definite epileptiform 
activity. Around 4½ to 5½ years of age she had a prolonged seizure-free period of several 
months on vigabatrin, sodium valproate and lamotrigine (after switching from vigabatrin, 
lamotrigine, phenobarbital and phenytoin). The mild developmental delay persisted. She was 
noted to have limited social communication. She was friendly but her behaviour was often 
challenging. Eye examination at 5 years of age was normal. 
 
At 6 years of age individual 2 was having clusters of seizures every 5 or 6 weeks. She had a 
pervasive developmental behaviour pattern in contrast to her brother who had profound 
developmental delay. Her seizures typically had a left-sided focal onset, occasionally with 
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generalization.  Her seizures were usually accompanied by vomiting and cyanosis.  On 
examination, her neurology was normal. Her gait stability had improved. OFC was 53.5 cm 
(+0.8 SD) and weight 23.48 kg (+0.3 SD). 
 
At 7 years of age individual 2’s social and communication skills were assessed to be at the level 
of 1 year 2 months while her motor skills were equivalent to 1 year 9 months. Autistic features 
were noted. Her height was 121.6 cm (+0.1 SD) and weight 27 kg (+1.0 SD). She had been 
seizure free for several months on lamotrigine and sodium valproate but then began having 
clusters of seizures again. Repeat MRI brain found atrophic changes particularly affecting the 
left parietal and occipital regions. An ictal EEG suggested a left fronto-termporal origin. 
Fluorodeoxyglucose positron emission tomography (FDG PET) found reduced uptake of tracer 
in the mesial and anterior temporal lobe on the left. Uptake elsewhere was normal. Individual 2 
underwent left anterior temporal lobectomy and partial amygdalo-hippocamptectomy at the age 
of 7 years 7 months of age. 
 
At 8 years 9 months of age individual 2’s social and communication skills were at the level of 1 
year 6 months and motor skills at the level of 22-24 months.  Her height was 132.8 cm (+0.2 SD) 
and weight 27.4 cm (-0.2 SD). EEG at 8 years and 10 months of age (on sodium valproate and 
lamotrigine) found only isolated sharp waves with phase reversal over the left hemisphere. There 
was no photosensitivity. Her seizures were well controlled at this stage and the lamotrigine was 
discontinued at 8 years and 11 months of age. 
  
At 9 years of age she was being educated in a special needs school. She was described as having 
a pervasive developmental disorder. Eye examination was normal with a minimal degree of 
hypermetropia. The brain surgery had helped for 2 years but attempts to wean her sodium 
valproate coincided with a recurrence of seizures. During seizures individual 2 would frown, 
become slightly confused, gag and sometimes vomit. Her right eye would start to twitch and this 
would often continue throughout the seizure. Her right arm and right leg would become weak 
and she would fall. She would become blue around the mouth, repeatedly swallow and smack 
her lips. Her whole body would jerk repeatedly. Seizures would occur at night or when she was 




A review when she was 11½ years of age showed that individual 2 was able to use about 30 
words and sing nursery rhymes. She was noted to have autistic features. Routines were important 
for her but she had good eye contact. She would lead people to objects she wanted. She was 
affectionate but often became frustrated and aggressive which was challenging for her family. 
There were no concerns about her vision or hearing. She was having occasional seizures 
associated with lip smacking, swallowing, asymmetric limb jerking (more on right side), with the 
event ending with her screaming. Neurological examination was normal. 
 
Individual 2’s genetic tests have included aCGH, single gene testing for ARX and FOXG1, and a 
30-gene infantile epilepsy panel. The results were all normal. Her other investigations have 
included a full suite of blood, urine and CSF investigations. The results were all normal. 
Echocardiography at 1 month of age found a tiny patent foramen ovale. Renal scan at 2 years 3 
months of age was normal. 
 
Summary of antiepileptic medications (Figure S3, current anticonvulsant drugs underlined): 
 
Sodium valproate  11-26 m(onths), 55m+ (long seizure-free period after re-introduction) 
Oxcarbazepine  14 m, 50m (no response, possibly more seizures on withdrawal)  
Clobazam  Intermittent (no response) 
Phenobarbital  Infancy, 52 m (irritable after loading)/ 
Vigabatrin   17m - 72m (initially reduced seizures frequency, difficult to wean) 
Levetiracetam  21m -25m, 39m-43m (some response to increased dose, better 
developmental progress after coming off) 
Topiramate   26m -33m (good control with vigabatrin and high dose topiramate, but 
parents reported cognitive impairment) 
Lamotrigine   31m - 108m, 155m+ (stopped after epilepsy surgery but recently restarted) 
Ethosuximide  46m -49m (no response) 
Phenytoin  54m -55m 
Lacosamide  67m - 70m (very sleepy) 
Rufinamide  70m 
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Eslicarbazepine 135m ("not really successful") 
Perampanel  147m - 151m (no seizures but behaviour deteriorated) 




This male individual (Decipher ID 260211) is the first child of unrelated White British parents. 
He has two younger brothers, the youngest of whom (individual 4) also has early-onset epilepsy 
and developmental delay. Echogenic intracardiac foci were noted at 20 weeks gestation. He was 
delivered by ventouse following a prolonged labour at 39 weeks gestation. His birth weight was 
3.4 kg (+0.1 SD). He did not require special care and was discharged home at 2 days of age. He 
presented at 1 month of age with persistent sleepiness and poor feeding. He had a septic screen 
including a lumbar puncture. It was noted on the ward that he was having recurrent apnoea 
(episodes of oxygen desaturation to 49%) and demonstrated some jerks and tonic posturing.  It 
was concluded he was having seizures. He was sedated and ventilated.  He was discharged home 
after a few days.  
 
At 2 months of age individual 3 had further episodes of hand stiffness and grunting. He was 
diagnosed with focal seizures. The seizure morphology evolved to include brief tonic spasms. By 
6 months of age he was having full flexor spasms. EEG confirmed hypsarrhythmia. Treatment 
with steroids and vigabatrin did not help. Individual 3 had global developmental delay and sat at 
2 years of age. He subsequently developed severe scoliosis.  
 
Individual 3 had a tonsillectomy at 5 years of age. He was noted to have an intermittent squint at 
7 years. He was educated in a special needs school. Puberty started early, at 9-10 years, with hair 
development. He had an orchidopexy at 14 years of age. Brain MRI was reported to be normal. 
EEG showed a slow spike wave background consistent with Lennox–Gastaut syndrome. 
 
Individual 3 was last reviewed at 19 years of age. He had severe learning disability, cortical 
visual impairment, and autism spectrum disorder. He could walk short distances with a frame. 
He tends to kneel-sit and could move around the floor in that position. He was very sensitive to 
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touch sensations. Individual 3 was non-verbal but vocalised and seemed to understand things that 
were said to him. He laughed when spoken to. He reached out for objects. He fed on soft solid 
food by mouth but required one-to-one feeding. He had severe gastroesophageal reflux disease. 
There had been three episodes of pneumonia over the previous two years. Individual 3 had 
periods of oral refusal possibly due to seizure activity or increased distress through constipation, 
leading to severe dehydration. Gastrostomy was being considered. He was not yet toilet trained. 
He was prone to chronic constipation. This required enemas and large doses of Movicol and 
washouts. Individual 3 also had hay fever and an urticarial reaction to peanuts. 
 
Individual 3 had not had periods of regression or episodes of non-convulsive status epilepticus 
(NCSE) like in his brother. He had a VNS implanted. His seizure types included frequent brief 
absences with lip quivering (e.g. 1-2 per hour), GTCS, head drops associated with colour change 
and then anger, and previous gelastic seizures. Individual 3 had frequent myocolonic jerks during 
sleep often associated with grunting. Fever did not increase seizures frequency. His seizures 
were less of a problem when ill. On examination, individual 3 had limited eye contact, low 
truncal tone, no tremor, gum hypertrophy, and scoliosis. His hand creases were normal. He had 4 
café au lait marks including a prominent one (~8 cm) on his back. His weight was 68 kg (-0.1 
SD) and OFC 57 cm (-0.2 SD).  
 
Individual 3’s genetic tests have included aCGH, and single gene testing for ARX and MECP2. 
 
Summary of antiepileptic medications (current anticonvulsant drugs underlined):  phenytoin, 
vigabatrin, lacosamide, clobazam, clonazepam, cannabidiol, perampanel (caused agitation), 
sodium valproate, levetiracetam (on 2-3 occasions), carbamazepine, topiramate, rufinamide, 




This male individual (Decipher ID 260212) is the third child of White British parents. He is the 
youngest brother of individual 3. Left-sided renal pelvis dilatation was diagnosed antenatally. He 
was born by elective caesarean section at 38 weeks gestation. He struggled with abdominal 
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pains, constipation, and gastroesophageal reflux as a baby but these improved over time. He 
presented with seizures at 6 months of age. These were described as brief focal seizures with his 
head and neck turning usually to the right with a clicking noise or licking of his lips. He sat at 11 
months and walked at 15 months. Concerns mainly revolved around his communication from 
early on as he was never verbal. 
 
Treatment with levetiracetam was started after one year of age and he was well controlled on this 
until 2½ years of age when valproate was added. At 2½ years of age he had a cluster of seizures 
associated with pyelonephritis and respiratory syncytial virus infection. The seizures were 
associated with vomiting, apnoea and cyanosis. The seizures were terminated with intravenous 
phenytoin and he was then put on maintenance phenytoin. Following this he developed NCSE 
and was noted to have epileptic spasms. His development regressed so that he could no longer 
sit, stand or feed himself. Intravenous lorazepam helped but his epileptic spasms and atypical 
absences became more intrusive. He was started on prednisolone, following which there was an 
improvement in his behaviour, functioning and seizures. 
 
Individual 4 had further admissions over the next few months. He was having multiple GTCS per 
day. His EEG at 2 years 7 months showed a modified hypsarrhythmia (high amplitude delta 
activity with frequent sharp and slow wave complexes, consistent with an epileptic 
encephalopathy). He was started on pyridoxine and pyridoxal phosphate without improvement. 
Seizures recurred following weaning of prednisolone with facial twitching, hypersalivation, 
epileptic spasms, and tonic seizures. A gastrostomy was placed due to poor feeding. 
 
At 3 years and 2 months of age he was admitted again with suspected NCSE. Medication 
changes improved his clinical state but he has been admitted occasionally (once or twice a year) 
since then diagnosed either clinically or on EEG to have NCSE. A medium-chain triglyceride 
(MCT)-based ketogenic diet was introduced at 3 years and 10 months of age. There was marked 
improvement in alertness over the next 6 weeks. However, he was worse when reviewed at 4 
years and 1 month of age. The ketogenic diet was changed to a classical diet at 4 years and 5 
months of age and weaned off at 4 years and 10 months of age. He was reluctant to walk, suck or 
swallow during this period. He experienced recurrent urinary tract infections despite prophylactic 
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trimethoprim. DMSA indicated that one kidney had 30% of normal function. He underwent 
unilateral nephrectomy at 4 years of age. 
 
At 10½ years of age, individual 4 had worsening seizures. He had been on nitrazepam and this 
was converted to clobazam. He was admitted for frequent tonic seizures and was given 
intravenous phenobarbitone. Maintenance phenobarbitone was started at 10 years and 10 months 
of age. He had a relatively stable period of several months on a combination of valproate, 
clobazam and lacosamide. He was still having several seizures per week but was generally happy 
and alert.  
 
At 11 years and 4 months of age he deteriorated and was re-admitted to hospital. He was having 
up to 300 atypical absence seizures per day. EEG revealed almost continuous generalised spike 
and slow wave activity. Ambulatory EEG was consistent with Lennox-Gastaut syndrome. He 
was having a mixture of atypical absences, tonic spasms and some tonic seizures. There was an 
attempt to wean him off nitrazepam, lacosamide and, subsequently, phenobarbitone. However, 
his seizures increased (occurring every few minutes), and he required HDU admission for 
intravenous midazolam. He was gradually weaned onto oral diazepam which proved useful. 
Ethosuximide and cannabidiol were started. Following weaning of the diazepam he again had 
frequent absence seizures and increased tonic seizures (up to 20+ per day). These improved with 
intravenous phenobarbitone and lorazepam. His functioning reduced markedly, and he became 
very subdued. He had prolonged periods of inactivity and looking glazed. This was unusual for 
individual 4 who was usually very active. Repeat EEG showed NCSE. Clobazam was 
recommenced leading to significant improvement and he was discharged after 2 months in 
hospital.  There were concerns about retching and vomiting towards the end of this inpatient 
stay. He was fed partly orally and partly by gastrostomy. He was treated with ondansetron, 
omeprazole and domperidone A pH study showing slight reflux to the upper oesophagus  
 
At 11 years and 8 months of age individual 4 was admitted again for several weeks. Initially, he 
was having up to 70 tonic seizures overnight which improved following an increase in clobazam. 
Due to concerns about self-mutilating behaviour, and subsequent raised γ-glutamyl transferase 
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(GGT) and alanine aminotransferase (ALT) he was slowly weaned off clobazam. He continued 
to be on sodium valproate although this was reduced slightly prior this prolonged admission. 
 
Individual 4 was last reviewed at 12 years of age. He had severe intellectual disability and an 
autism spectrum disorder. He continued to have prolonged admissions for recurrent episodes of 
NCSE associated with frequent vomiting. He lost motor skills during periods of frequent 
seizures. When he was well, he could walk independently, though he required supervision and 
often one-hand support. He would have eye contact and smile responsively as well as vocalise. 
He did not have recognisable speech. He often ground his teeth. He had not experienced early 
puberty. Individual 4 was suspected to have cortical visual impairment. He walked with a broad-
based unsteady gait. On examination he had eczema, hypermobile joints and mild hirsutism. 
Neurologically he had low truncal tone, mild scoliosis, tight hamstrings but no lateralising signs. 
His weight was 39 kg (+0.1 SD) and OFC 53 cm (-1.3 SD). 
 
Individual 4’s genetic tests have included aCGH, and single gene testing for SLC2A1 and 
STXBP1. Other investigations with normal results have included CSF neurotransmitters and 
pyridoxal phosphate, muscle biopsy (histopathology and respiratory chain enzymes), urine 
AASA and transferrin isoelectric focusing. Brain MRI scan at 1½ years of age was normal. Brain 
MRI at 12 years of age showed slight cerebellar volume loss and decreased volume of the 
splenium of the corpus callosum. There was a small arachnoid cyst in the left middle cranial 
fossa. There was possible increased signal and swelling of the hippocampi bilaterally which may 
have reflected seizure activity. Individual 4 had a 3T MRI brain scan at 13 years of age which 
showed symmetrical T2 hyperintensity of the hippocampal body and head with loss of definition 
of the internal architecture on all the sequences. There was no evidence of underlying diffusion 
restriction. Review of a previous MRI scan from 2½ years of age showed similar changes. 
 
Summary of antiepileptic medications (current anticonvulsant drugs underlined): sodium 
valproate, levetiracetam, ethosuximide (caused vomiting), topiramate, lacosamide, rufinamide 
(caused vomiting), lamotrigine (associated with nonconvulsive status), phenytoin (not used since 
2½ years of age due to concerns that it resulted in NCSE when maintenance dose was given), 
phenobarbital (some benefit though not significant recently with tonic or absence seizures), 
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clobazam (useful for NCSE), nitrazepam (longstanding use), prednisolone (none since 2 years of 
age), lorazepam (used for NCSE and improved tonic seizures), diazepam, cannabidiol 




This male individual is the first child of unrelated White Canadian parents. He was born by 
spontaneous vaginal delivery following an uncomplicated pregnancy at 39+3 weeks gestation. 
His biometry at birth was weight 3.67 kg (+0.7 SD), OFC 36.5 cm (+1.5 SD) and length 53.5 cm 
(+1.7 SD). He had mild hyperbilirubinemia which did not require treatment. There was no 
arthrogryposis or talipes. He began having seizures at 5 days of age. These involved repetitive 
right eye blinking, gaze and head deviation, repetitive swallowing and clicking noises. Seizures 
lasted 1 to 2 minutes and occurred 1 to 5 times a day. MRI brain at 1 month of age found no 
structural abnormalities and no evidence of acute ischemia. EEG was abnormal and showed 
epileptiform discharges from the right temporal region and independent epileptiform discharges 
from the left temporal region. This suggests multiple epileptogenic foci. Some of the events were 
associated with leg twitching. 
 
Individual 5 smiled social at 8 weeks of age but underwent a period of regression around 4 
months of age. Individual 5 was last reviewed at 2 years and 3 months of age. He had severe 
developmental delay. He was not talking, sitting or standing independently. He would 
occasionally (but not consistently) fix and follow light. Individual 5 was gastrostomy fed due to 
problems with suck and swallow coordination. He had constipation, cortical visual impairment, 
moderate conductive hearing loss, hypothyroidism, osteopenia, and gastroesophageal reflux 
disease. He continued to have focal dyscognitive seizures. Individual 5 had periodic abnormal 
posturing (decorticate and opisthotonus) as well as dystonic episodes and myoclonus.  On 
examination, individual 5 was not dysmorphic. Growth parameters (at 22 months of age) were 
weight 15.8 kg (+2.4 SD) and OFC 48.5 cm (-1.1 SD). Neurological examination found 
generalised hypotonia with no contractures or scoliosis. His knee reflexes were normal with no 




Individual 5’s most recent EEG was done at 2 years of age. This showed almost continuous 1.5-2 
Hz sharp and slow wave complexes during sleep and also appearing frequently during 
wakefulness. The electroclinical features were suggestive of Lennox-Gastaut syndrome. 
Individual 5’s genetic testing has included aCGH and epilepsy gene panel (Courtagen epiSEEK) 
which were both normal. Extensive metabolic investigation including lactate, plasma amino 
acids, urine organic acids and urine metabolic screen were all negative. 
 
Summary of antiepileptic medications:  
Phenobarbital, valproic acid (individual 5 experienced abdominal pain with valproic acid), 
clobazam, rufinamide, levetiracetam, ACTH, cannabis, vigabatrin, lamotrigine, topiramate, and 





This male individual (Decipher ID 264848) is the child of unrelated white British parents. He has 
a brother with infantile-onset epilepsy, developmental delay and behavioural problems, and a 
maternal aunt diagnosed with cerebral palsy and epilepsy.  Further clinical evaluation or genetic 
testing of individual 6’s brother or parents has not been possible. 
 
The pregnancy with the individual 6 was uncomplicated. Scans were normal during pregnancy 
and there was no bleeding. He was born by spontaneous vaginal delivery at 38 weeks gestation. 
His birth weight was 2.6 kg (-1.2 SD). He was admitted to the neonatal unit within 24 hours 
following a cyanotic episode.  Investigations showed gastroesophageal reflux and he was treated 
with Gaviscon. He was discharged home after 3 weeks. His mother continued to be concerned 
during infancy about the number of cyanotic episodes individual 6 was having.  After several 
months he was admitted to hospital. In retrospect, it was realised the cyanotic episodes may have 
been seizures. In addition, he was found to have an atrial septal defect.   
 
Individual 6 went on to be diagnosed with global developmental delay, seizures, and autism. He 
sat at 1 year and walked at 2 years and 3 months. Individual 6 was last assessed at 5 years 8 
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months. His OFC was 49 cm (-2.6 SD). His examination findings included strabismus and coarse 
facial features. Genetic investigations of individual 6 have included aCGH and testing for Fragile 




This male individual is the child of consanguineous Chinese parents (half-first cousins). He had a 
family history of epilepsy in a paternal grand uncle. He was delivered by Caesarean section at 
35+2 weeks gestation following an uncomplicated pregnancy. His birth weight was 2.5 kg (+0.1 
SD). There were no concerns in the neonatal period. Individual 7 smiled socially at 3 months, sat 
unsupported at 9 months and walked independently at 13 months. The first concerns were at 6 
months of age when he developed focal seizures. 
 
Individual 7 experienced a period of regression at 14 months of age. He lost the ability to walk, 
sit, or smile socially. EEG at 1 year and 11 months of age showed generalized spike and slow-
spike waves. There was atypical hypsarrhythmia and intermittent burst suppression during sleep. 
Clusters and isolated spasms were detected when he was awake. At 3 years and 2 months his 
head circumference was 48cm (-2.6 SD). 
 
Individual 7 was last reviewed at 5 years and 8 months old. He had severe developmental delay 
and intractable epilepsy. He was not yet talking, walking or toilet trained. He was fed orally with 
pureed food, but choking was a frequent problem. He had problems with sleep disturbance. His 
predominant seizure type are focal seizures. He has also had myoclonic seizures, epileptic 
spasms and GTCS. On examination his length was 110 cm (-0.8 SD) and weight 18kg (-0.9 SD). 
Neurological examination found limb hypertonia with positive Babinski sign and ankle clonus. 
There was no strabismus, joint contractures or abnormal movements. 
 
Individual 7's genetic testing has included aCGH. The results were normal. Metabolic 
investigations were also negative. Brain MRI at 3 years and 2 months of age showed cerebral 




Summary of antiepileptic medications (current anticonvulsant drugs underlined): Levetiracetam, 
valproate, clonazepam, carbamazepine (made symptoms worse), zonisamide (worked well), 
oxcarbazepine, lamotrigine (allergic reaction), ACTH (worked well). 
47 
 
Genomics England Research Consortium 
 
Ambrose, J. C.,1 Arumugam, P.,1 Baple, E. L.,1 Bleda, M.,1 Boardman-Pretty, F.,1,2 Boissiere, J. 
M.,1 Boustred, C. R.,1 Brittain, H.,1 Caulfield, M. J.,1,2 Chan, G. C.,1 Craig, C. E. H.,1 Daugherty, 
L. C.,1 de Burca, A.,1 Devereau, A.,1 Elgar, G.,1,2 Foulger, R. E.,1 Fowler, T.,1 Furió-Tarí, P.,1 
Giess A.,1 Hackett, J. M.,1 Halai, D.,1 Hamblin, A.,1 Henderson, S.,1,2 Holman, J. E.,1 Hubbard, 
T. J. P.,1 Ibáñez, K.,1,2 Jackson, R.,1 Jones, L. J.,1,2 Kasperaviciute, D.,1,2 Kayikci, M.,1 
Kousathanas, A.,1  Lahnstein, L.,1 Lawson, K.,1 Leigh, S. E. A.,1 Leong, I. U. S.,1 Lopez, F. J.,1 
Maleady-Crowe, F.,1 Mason, J.,1 McDonagh, E. M.,1,2 Moutsianas, L.,1,2 Mueller, M.,1,2 
Murugaesu, N.,1 Need, A. C.,1,2 Odhams, C. A.,1 Orioli A.,1 Patch, C.,1,2 Perez-Gil, D.,1 Pereira, 
M. B.,1 Polychronopoulos, D.,1 Pullinger, J.,1 Rahim, T.,1 Rendon, A.,1 Riesgo-Ferreiro, P.,1 
Rogers, T.,1 Ryten, M.,1 Savage, K.,1 Sawant, K.,1 Scott, R. H.,1 Siddiq, A.,1 Sieghart, A.,1 
Smedley, D.,1,2 Smith, K. R.,1,2 Smith, S. C.,1 Sosinsky, A.,1,2 Spooner, W.,1 Stevens, H. E.,1 
Stuckey, A.,1 Sultana, R.,1 Tanguy M.,1 Thomas, E. R. A.,1,2 Thompson, S. R.,1 Tregidgo, C.,1 
Tucci, A.,1,2 Walsh, E.,1 Watters, S. A.,1 Welland, M. J.,1 Williams, E.,1 Witkowska, K.,1,2 Wood, 
S. M.,1,2 Zarowiecki, M.,1 
 
1. Genomics England, London, UK 
 









Figure S1.  FHF2AWT, FHF2AR11C and FHF2AR14T proteins interact with Nav1.6.  Neuro2A 
cells were transiently transfected with expression vectors indicated at top of figure.  Total lysates 
or anti-FHF2 immunoprecipitates (IP) were subjected to gel electrophoresis and immunoblotting 
with anti-FHF2 or anti-pan-Nav antibodies.  Nav1.6 is detected in anti-FHF2 immunoprecipitates 









Figure S2. Antiepileptic medications given to individual 1. Timeline illustrating the 











Figure S3. Antiepileptic medications given to individual 2. Timeline illustrating the 








Variant FHF2, c.31C>T, p.(Arg11Cys) FHF2, c.41G>C, p.(Arg14Thr) FHF2, c.32G>C, p.(Arg11Pro) 
Algorithm Score Prediction Score Prediction Score Prediction 
       
SIFT 0.001 Damaging 0 Damaging 0.057 Tolerable 










LRT - - - - - - 






MutationAssessor 1.935 Low 1.935 Low 1.935 Low 
FATHMM -1.94 Damaging -1.92 Damaging -1.93 Damaging 
PROVEAN -2.27 Tolerable -1.99 Tolerable -1.96 Tolerable 
VEST3 0.791 Damaging 0.702 Damaging 0.872 Damaging 
MetaSVM 0.383 Damaging 0.305 Damaging 0.087 Damaging 
MetaLR 0.666 Damaging 0.594 Damaging 0.548 Damaging 
M-CAP 0.473 Damaging 0.388 Damaging 0.322 Damaging 
CADD 22.4 Damaging 22.9 Damaging 22.8 Damaging 
DANN 0.999 Damaging 0.973 Tolerable 0.994 Damaging 
FATHMM_MKL 0.893 Damaging 0.97 Damaging 0.97 Damaging 
Eigen - - - - - - 
GenoCanyon 1 Damaging 1 Damaging 1 Damaging 
fitCons - - - - - - 
GERP++ 3.36 Conserved 4.29 Conserved 4.29 Conserved 
phyloP 2.668 Conserved 7.364 Conserved 7.364 Conserved 
phastCons 1 Conserved 1 Conserved 1 Conserved 
SiPhy 10.765 Nonconserved 15.342 Conserved 15.342 Conserved 
REVEL 0.697 Damaging 0.733 Damaging 0.687 Damaging 
ReVe 0.889 Damaging 0.863 Damaging 0.918 Damaging 
ClinPred 0.86299818 Pathogenic 0.90703922 Pathogenic 0.812778 Pathogenic 
 








Electrophysiology and immunochemical analyses of plasmid-transfected Neuro2A cells 
 
All procedures parallel those we have described previously.1,2  The Nav1.6 expression plasmid 
(pIRESneo3-Nav1.6TTXr) bears the tetrodotoxin (TTX) binding site substitution Y371S, rendering 
the channel resistant to TTX.  FHF2A/GFP bicistronic expression plasmid pIRES2-FHF2A-
ZsGreen drives coexpression of untagged FHF2A and green fluorescent protein, while pIRES2-
ZsGreen expresses fluorescent protein only.  Missense substitutions p.R11C or p.R14T were 
introduced into the pIRES2-FHF2A-ZsGreen plasmid using complementary mutagenic primers 
and PfuTurbo DNA Polymerase (Agilent). 
 
Neuro2A cells were used for expression of sodium channels and FHFs by Lipofectamine 
(LFN2000)-mediated plasmid transfection at a 2:1 ratio of Nav- and FHF-expressing plasmids. 
For protein expression analysis, transfected cells were lysed after 24 hour culture. For 
electrophysiology, transfected cells were trypsinized, plated onto coverslips, and maintained for 
24–48 hours before transfer to the recording chamber. 
 
For analysis of Nav1.6TTXr-mediated inward sodium currents, O2:CO2 (95:5; carbogen)-bubbled 
extracellular solution contained the following (in mM): 109 NaCl, 26 NaHCO3, 10 HEPES, 4.7 
KCl, 11 glucose, 1.2 MgCl2, 2 CaCl2, 0.2 CdCl2, 3 myo-inositol, 2 Na pyruvate, 0.001 TTX 
(buffered to pH 7.2 with NaOH), and the intracellular pipette solution (Pipette 
Solution I) contained 104 CsF, 50 tetraethylamine chloride (TEA), 10 HEPES, 5 glucose, 2 
MgCl2, 10 EGTA, and 2 Na2ATP, 0.2 Mg-GTP (buffered to pH 7.2 with CsOH). The recording 
chamber was set within a Nikon EF600 microscope equipped with 40X water-immersion 
objective and video camera. Transfected cells were identified by green fluorescence and whole-
cell configuration was induced after achieving a 5–20 Gohm seal. Wide pipette tips were used 
yielding a series resistance of 2.5–5 Mohm following whole cell access. Voltage-clamp was 
conducted using an Axopatch 200B amplifier, Digidata 1322 digital/analog interface, and 
pCLAMP9 software (Molecular Devices). Recording signals were filtered at 5 kHz and digitized 
at 20 kHz.  For measurements of evoked sodium currents, capacitive and leak currents were 





Protocols for measuring voltage dependence of sodium channel steady-state inactivation and 
accumulation into and recovery from long-term inactivation were described previously.1 To 
assay steady state inactivation, cells were depolarized for each sweep from -110 mV holding 
potential to test potentials between -110 mV to -20 mV in 5 mV intervals for 80 ms after which 
sodium current from non-inactivated channels was induced by further depolarization to -10 mV.  
To assay accumulating long-term inactivation, cells were subjected to four consecutive 
depolarizations from -90 mV to 0 mV for 16 ms separated by 40 ms -90 mV recovery phases.  
Progressively decreasing sodium current in the second, third, and fourth depolarizations reflects 
long-term channel inactivation.  To assay for recovery rate from long-term inactivation, cells 
were subjected to three successive depolarizations from -90 mV to 0 mV to accumulate long-
term inactivation, and a fourth depolarization was given at time intervals ranging from 20 ms to 
1 s.  Recovery from intrinsic fast inactivation occurs within 20 ms, so fraction recovery from 
long-term inactivation at time t was calculated as {INa(t) - INa(20)}/{INa(0) - INa(20)}, where 
INa(0) is the sodium current generated from the first depolarization, INa(20) is the sodium current 
from the fourth depolarization following 20 ms recovery, and INa(t) is the sodium current from 
the fourth depolarization following recovery for time t.  All data points in the graphs are 
expressed as mean +/- standard error of values from all (n) recorded cells. Statistical significance 
of differences in data point values between pairs of transfected cells was assessed by Student T 
test. 
 
For biochemical analyses, cells were lysed in buffer containing (in mM) 137 NaCl, 20 Tris pH 
7.4, 2 EDTA, 25 β-glycerophosphate, 2 Na4P2O7, 1 Na3VO4, 10% glycerol, 1% Triton X-100 
and then clarified by high-speed centrifugation.  Lysates were electrophoresed through 4%-20% 
polyacrylamide SDS gels directly or after immunoprecipitation with rabbit polyclonal antibodies 
against the C-terminal domain of FHF2.1  Proteins were electrophoretically transferred from gel 
to polyvinylidene difluoride (PVDF) membrane and probed with either the same FHF2 
antibodies or with pan-sodium channel monoclonal antibody K58/35 (Sigma Aldrich) followed 





X-chromosome inactivation analysis 
Two assays comprising amplification of a short fragment of X chromosome (amplimer) were 
used to determine the activation status of each X chromosome.  Each amplimer contains a 
polymorphic marker adjacent to the promoter of a gene which is unmethylated on the active X 
chromosome and methylated on the inactive chromosome.  The two genes investigated were the 
androgen receptor AR and ZNF261 (ZMYM3; DXS6673E).  Both genes are in Xq13.  Prior to 
amplification, both assays employ methylation-sensitive restriction enzymes, HpaII and CfoI, 
which cut at the promoter site on the active (unmethylated) but not on the inactive (methylated) 
X chromosome, using previously described methods.3,4 To calculate the X-inactivation ratio, 
each sample was set up in duplicate: one digest and one mock digest without enzyme.  Both were 
then amplified by PCR using a fluorescently labelled primer.  The ratios of the heights of the two 
peaks were then compared between the undigested and digested samples. To evaluate the 
significance of patterns of X inactivation the ratios are compared with data from a sample of 
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